Search Results
Your search for ,VIA matches 1395 pages
Showing 951 - 1000Novel Approach to PET/CT Imaging May Predict Location and Extent of Primary Prostate Cancer
With surgical removal at the front line of defense against prostate cancer, oncologists are considering prostate-specific molecular imaging at the point of initial biopsy and preoperative planning to root out the full extent of disease, researchers showed at the 2016 Annual Meeting of the Society...
Analysis of Cerebrospinal Fluid for D-2-Hydroxyglutarate May Detect Malignant Brain Tumors Nonsurgically
When a brain tumor is suspected, its presence is usually confirmed by anatomic imaging such as computed tomography (CT) or magnetic resonance imaging (MRI). But through imaging, not much about the tumor molecularly can be learned. Surgery and a biopsy are necessary to get a glimpse of the cancer...
Primary Care Visits Result in More Colorectal Cancer Screening, Better Follow-up
People who visit their primary care physicians are more likely to get potentially life-saving colon cancer screenings and follow-up on abnormal stool blood test results—even in health systems that heavily promote mail-in home stool blood tests that don’t require a doctor visit, a study...
Black Cohosh
Scientific Name: Cimicifuga racemosa Common Names: Black snakeroot, rattlesnake root, squawroot, bugbane, bugwort Brand Names: Remifemin, Menofem, Klimadynon Overview A perennial plant native to the eastern United States and Canada, black cohosh root was used by Native Americans to treat colds,...
Inside Knowledge From a Cancer Survivor
Curtis Pesmen is a well-regarded writer who has authored six books of nonfiction as well as numerous articles for publications such as Esquire and The New York Times. He also has served as founding editor of LIVESTRONG Quarterly and often speaks and writes on patient advocacy. Shortly after...
Creating Hybrid Academic-Community Cancer Centers to Improve Patient Care
Five years ago, the Helen F. Graham Cancer Center and Research Institute at Christiana Care Health System in Newark, Delaware, and The Wistar Institute, a National Cancer Institute (NCI)-designated biomedical research center, in Philadelphia, Pennsylvania, joined forces to collaborate on...
USPSTF Issues New Recommendations for Colorectal Cancer Screening
As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) has issued new recommendations for colorectal cancer screening. In brief, the USPSTF recommends colorectal cancer screening starting at age 50 years and continuing until age 75 years (grade A recommendation = “The USPSTF...
SNMMI 2016: VASH Collimator Allows Three-Dimensional Imaging of the Breast With Less Radiation
Preliminary tests have demonstrated that a new device may enable existing breast cancer imagers to provide up to six times better contrast of tumors in the breast, while maintaining the same or better image quality and halving the radiation dose to patients. The advance is made possible by a new...
SNMMI 2016: PET/CT Imaging of Prostate Cancer With Specific Agent May Be an Accurate Prebiopsy/Preoperative Guide
With surgical removal at the frontline of defense against prostate cancer, oncologists are considering prostate-specific molecular imaging at the point of initial biopsy and preoperative planning to root out the full extent of disease, researchers showed at the 2016 Annual Meeting of the Society of ...
SNMMI 2016: CT-Based Lean Body Mass Calculations Improve Accuracy of PET for Patients With Cancer
Patients with cancer often experience significant fluctuations in weight and lean body mass. Neglecting to account for these changes can prevent clinicians from obtaining precise data from molecular imaging, but a new method of measuring lean body mass takes changes in individual body...
SIRIUS Trial Heralds a New Era of Promise in Treating Resistant Myeloma
Multiple myeloma cells uniformly overexpress CD38.1 Daratumumab (Darzalex), a CD38-targeting human IgG1 kappa monoclonal antibody, has been evaluated in a series of phase I/II trials involving patients with relapsed or relapsed and refractory myeloma who have received at least two or more prior...
Learning About Fertility Is Important to Young Patients With Cancer
It is more and more common for people to wait until their 30s or 40s to have children. Consequently, many young adults have not completed their desired childbearing when they are diagnosed with cancer. Cancer treatments can impair fertility directly (usually via gonadotoxicity from chemotherapy,...
Ovarian Suppression in Premenopausal Women With Estrogen Receptor–Positive Breast Cancer
Oophorectomy was the first proposed form of endocrine therapy for women with breast cancer. Over 100 years ago, Thomas Nunn reported a relationship between menopause and regression of breast cancer.1 This incited interest in the induction of menopause as an anticancer therapy, and in 1986, a...
Nivolumab in Classical Hodgkin Lymphoma
On May 17, 2016, nivolumab (Opdivo) was granted accelerated approval for treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation and post-transplantation brentuximab vedotin (Adcetris).1,2 Continued approval for ...
PD-L1 Inhibitor Atezolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.On May 18, 2016, the PD-L1 (programmed cell death ligand 1)...
Chemotherapy After Radical Prostatectomy May Benefit African Americans and High-Risk Patients
A new U.S. Department of Veterans Affairs (VA) study suggests that African American men and men with a higher tumor stage may benefit from adjuvant chemotherapy following radical prostatectomy.1 According to prespecified analysis of these two “high–risk” subgroups, patients with ≥ T3b disease had a ...
ASCO Statement on Human Papillomavirus Vaccination for Cancer Prevention
As reported in the Journal of Clinical Oncology by Howard H. Bailey, MD, of the University of Wisconsin Carbone Cancer Center, and colleagues, ASCO has released a statement on increasing human papillomavirus (HPV) vaccination to prevent HPV-related cancers in the United States.1 In the United...
Expert Point of View: Paul G. Richardson, MD
Study discussant Paul G. Richardson, MD, the RJ Corman Professor of Medicine at Harvard Medical School and the Jerome Lipper Multiple Myeloma Chair at Dana-Farber Cancer Institute, Boston, commented, “The evolving role of monoclonal antibodies in multiple myeloma has been worth the wait. You can...
Vulnerable Hospitals, Cancer Surgery Readmissions, and Penalizing Payment Programs
Readmission rates after complex cancer operations tend to be higher in hospitals that are considered to be vulnerable because they serve as safety nets in their communities or have a high number of Medicaid patients. Reasons for higher readmission rates are highly complex and involve socioeconomic...
ASCO Endorses European Association of Urology Guideline on Muscle-Invasive and Metastatic Bladder Cancers
As reported in the Journal of Clinical Oncology by Matthew I. Milowsky, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and colleagues,1 ASCO has endorsed the European Association of Urology clinical practice guideline on muscle-invasive and metastatic bladder...
Enhance Your Annual Meeting Experience With Attendee Resources
Next month, more than 30,000 oncology professionals will gather in Chicago for the 2016 ASCO Annual Meeting. This year’s theme, “Collective Wisdom: The Future of Patient-Centered Care and Research,” highlights the value of the combined knowledge of the global oncology community, spanning across...
Venetoclax for Previously Treated Chronic Lymphocytic Leukemia With 17p Deletion
On April 11, 2016, venetoclax (Venclexta) was approved for treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by a U.S. Food and Drug Administration (FDA)-approved test, who have received at least one prior therapy.1,2 The accelerated approval was based...
Fitness: Can Exercise Lengthen Survival in Patients With Cancer?
Integrative Oncology is guest edited by Barrie R. Cassileth, MS, PhD, of Memorial Sloan Kettering Cancer Center, New York. Regular physical activity has long been associated with decreased risk of disease, including many types of cancer. Such benefits may translate into increased life expectancy...
Induced Phenotype Targeted Therapy to Overcome Tumor Heterogeneity
In a study reported in the Journal of the National Cancer Institute, Lee and colleagues designed a caspase-3–specific activated prodrug containing doxorubicin linked to a peptide moiety (DEVD-S-DOX), which is cleaved by caspase-3 at apoptosis. Apoptosis was induced in C3H/HeN mammary tumor-bearing...
Using Telemedicine to Reduce Wait Times for Veterans
John Farrow, a 67-year-old Vietnam veteran, had not been able to sleep for days. A week ago, his primary care doctor at his local outpatient Veterans Administration (VA) clinic told him that his prostate-specific antigen (PSA) blood level was rapidly increasing, and his prostate was abnormal on...
Potential Role for HSP70 Peptide Aptamer in Restoring Anticancer Immune Response
Exosomes can activate myeloid-derived suppressor cells via interaction of membrane heat shock protein 70 (HSP70) with Toll-like receptor 2 (TLR2) on the myeloid-derived suppressor cell. As reported in the Journal of the National Cancer Institute, Gobbo and colleagues found that the A8 peptide...
Potential Biomarker for Carfilzomib Activity in CLL
Carfilzomib (Kyprolis) is active in B-cell neoplasms but exhibits heterogeneous activity in chronic lymphocytic leukemia (CLL) samples. As reported in Clinical Cancer Research, Lamothe and colleagues examined the mechanism by which carfilzomib induces CLL cell death. In studies using CLL patient...
Updates on Elotuzumab in Multiple Myeloma Show Persistence of Benefit
Studies presented at the 2015 ASH Annual Meeting bolstered support for elotuzumab (Empliciti) given in combination with lenalidomide (Revlimid) for the treatment of multiple myeloma. Elotuzumab is an immunostimulatory monoclonal antibody. It has a dual mechanism of action, directly activating...
ASCO Statement on Human Papillomavirus Vaccination for Cancer Prevention
As reported in the Journal of Clinical Oncology by Bailey et al, ASCO has released a statement on increasing human papillomavirus (HPV) vaccination to prevent HPV-related cancers in the United States. In the United States, HPV is estimated to cause approximately 99.7% of cervical cancers, 60% of...
AACR 2016: Report Identifies Considerations for Alternative Payment Models for Cancer Care
A roundtable convened by the Turning the Tide Against Cancer initiative, composed of a multidisciplinary group of stakeholders, put forth five policy considerations that are critical to ensuring the delivery of high-quality oncology care while supporting innovation. The report was published by...
Next-Generation Sequencing Assay May Permit Accurate Detection of Mismatch Repair Deficiency in Colorectal Cancer
Use of a custom next-generation sequencing assay may accurately predict mismatch repair deficiency on the basis of mutational load in colorectal cancer, according to a report by Stadler et al in the Journal of Clinical Oncology. Study Details The study involved data from 224 patients with...
ASCO Endorses European Association of Urology Guideline on Muscle-Invasive and Metastatic Bladder Cancer
As reported in the Journal of Clinical Oncology by Matthew I. Milowsky, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and colleagues, ASCO has endorsed the European Association of Urology clinical practice guideline on muscle-invasive and metastatic bladder cancer. ...
Minimal Residual Disease in AML: Worth Looking?
As summarized in this issue of The ASCO Post, Ivey and colleagues demonstrated that assessing for NPM1-mutated gene transcripts by reverse-transcriptase quantitative polymerase chain reaction assay is a feasible approach for measuring minimal residual disease after acute myeloid leukemia (AML)...
Assessment of Survival Impact of Atypical Responses With Pembrolizumab Treatment in Advanced Melanoma
As reported by Hodi et al in the Journal of Clinical Oncology, use of conventional Response Evaluation Criteria in Solid Tumors (RECIST) to assess response may have underestimated the benefit of treatment with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keytruda) in the...
Benefiting From Mind-Body Therapy
My diagnosis of early-stage breast cancer at age 35 was a shock, also because I come from a family with no history of cancer. In disbelief, I was literally speechless—I lost my voice completely for several days. I grew up in the former Soviet Union and then in the newly independent Kyrgyzstan. My...
NCCN Awards 10 Grants for Provider Performance and Quality in Treatment of Metastatic Breast Cancer Initiatives
The National Comprehensive Cancer Network® (NCCN) Oncology Research Program (ORP), in collaboration with Pfizer Independent Grants for Learning & Change (IGLC), has awarded 10 grants for project proposals to develop and adopt evidence-based initiatives to improve patient care and outcomes in...
Occult Metastasis on Immunohistochemistry May Affect Survival in Stage I NSCLC
Mature results of the Cancer and Leukemia Group B 9761/Alliance study, reported in the Journal of Clinical Oncology by Martin et al, indicate that occult metastases detected by immunohistochemistry in N2 lymph nodes may be associated with poorer overall survival after resection in clinical stage I...
Obinutuzumab in Relapsed or Refractory Follicular Lymphoma
On February 26, 2016, obinutuzumab (Gazyva) was approved for use in combination with bendamustine (Bendeka, Treanda) followed by obinutuzumab monotherapy for treatment of patients with follicular lymphoma who have relapsed after or are refractory to a rituximab (Rituxan)-containing regimen.1,2...
Study Supports an Immune Effect of Chemoradiation in Head and Neck Cancer
Definitive radiation, with or without chemotherapy, induces a combination of immune-stimulating and inhibitory effects in patients with squamous cell carcinoma of the head and neck, according to research presented by Jonathan Schoenfeld, MD, MPhil, MPH, at the 2016 Multidisciplinary Head and Neck...
No Significant Survival Advantage for Rigosertib in High-Risk Myelodysplastic Syndromes, but Subgroups May Benefit
As reported in The Lancet Oncology by Garcia-Manero et al, the phase III ONTIME trial showed that treatment with the Ras mimetic rigosertib did not significantly improve overall survival vs best supportive care in patients with high-risk myelodysplastic syndromes after failure of hypomethylating...
Resensitization to Crizotinib via Acquisition of Lorlatinib ALK Resistance Mutation Reported in Patient With NSCLC
As reported by Shaw et al in The New England Journal of Medicine, a woman with metastatic ALK-rearranged non–small cell lung cancer (NSCLC) who had received multiple prior therapies, including the first- and second-generation ALK inhibitors crizotinib (Xalkori) and ceritinib (Zykadia),...
Eribulin Mesylate in Advanced Liposarcoma Previously Treated With an Anthracycline
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 28, 2016, eribulin mesylate (Halaven) was approved for...
Carfilzomib Plus Dexamethasone in Previously Treated Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 21, 2016, carfilzomib (Kyprolis) was approved for use in ...
Radiolabeled Somatostatin Analog May Represent A Paradigm Change in the Treatment of Neuroendocrine Tumors
A radiolabeled somatostatin analog compound, 177Lu-DOTA0-Tyr3-Octreotate (Lu-177 dotatate), reduced the risk of disease progression or death by 79% in the international phase III NETTER-1 population of previously treated, advanced neuroendocrine tumors of midgut origin.1 Lu-177 dotatate belongs to...
Mistletoe
The use of dietary supplements by patients with cancer has increased significantly over the past 20 years despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and...
A Surgeon’s Inspiring Journey to Death
Every so often, a memoir comes along in which the story speaks to universal themes. For that magic to occur, the author must step aside at times and let others tell their story, too. Moreover, the writing must be clear, vibrant, and above all else honest to the core. The recently published memoir...
Nivolumab Plus Ipilimumab in Unresectable or Metastatic Melanoma Regardless of BRAF Mutation Status
On January 23, 2016, the indication for nivolumab (Opdivo) plus ipilimumab (Yervoy) in unresectable or metastatic melanoma was expanded through accelerated approval to include patients regardless of BRAF V600 mutation status.1 The combination was previously approved for treatment of patients with...
Conquer Cancer Foundation Awards Grants to Drive International Cancer Care Advances
The Conquer Cancer Foundation of ASCO has awarded four 2016 International Innovation Grants to organizations developing projects with the potential to revolutionize cancer control in low- and middle-income countries. This year’s grants will support research in India, Nepal, Uganda, and the...
Ofatumumab for Extended Treatment of Patients With Recurrent or Progressive Chronic Lymphocytic Leukemia
On January 19, 2016, ofatumumab (Arzerra) was approved for extended treatment of patients in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL).1,2 Ofatumumab was previously approved for treatment of untreated patients...
Expanded Approval of Pembrolizumab in Unresectable or Metastatic Melanoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 18, 2015, approval of the programmed cell death...
